Physician profile

Gilad M Jaffe

Pulmonary Disease · San Diego, CA

NPI 1891157392

$1,273.16

in general payments reported to CMS, 2019-2025

11 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$299.76

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boehringer Ingelheim Pharmaceuticals, INC. $414.98 2021-2022
La Jolla Pharmaceutical Company $235.00 2020-2021
Pulmonx Corporation $163.97 2023 Zephyr Delivery Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve
Astrazeneca Pharmaceuticals Lp $159.09 2022-2023 Breztri
Actelion Pharmaceuticals US, INC. $144.37 2022-2023 Opsumit, Uptravi
Glaxosmithkline, LLC. $68.05 2022-2023 Trelegy Ellipta
Grifols USA, LLC $24.24 2023 Prolastin-C Liquid
Electromed, INC. $21.25 2023 Smartvest
Genzyme Corporation $15.10 2022
Amgen INC. $13.60 2022
United Therapeutics Corporation $13.51 2023 Tyvaso

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gilad M Jaffe

$1,273.16

in general payments reported 2019-2025

Years
2020-2023
Top company
Boehringer Ingelheim Pharmaceuticals, INC.

https://glasscript.com/doctor/7449297/gilad-m-jaffe

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.